Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort. Women with a BRCA1 or BRCA2 mutation were identified from an international registry; 5,783 women completed a baseline questionnaire and ≥ one follow-up questionnaires. Women were observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of most recent follow-up. Hazard ratios (HRs) for cancer incidence and all-cause mortality associated with oophorectomy were evaluated using time-dependent survival analyses. After an average follow-up period of 5.6 years, 186 women developed either ovarian (n = 132), fallopian (n = 22), or peritoneal (n = 32) cancer, of whom 68 have died. HR for ovarian, fallopian, or peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P < .001). Among women who had no history of cancer at baseline, HR for all-cause mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P < .001). Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality.

Finch AP ，Lubinski J ，Møller P ，Singer CF ，Karlan B ，Senter L ，Rosen B ，Maehle L ，Ghadirian P ，Cybulski C ，Huzarski T ，Eisen A ，Foulkes WD ，Kim-Sing C ，Ainsworth P ，Tung N ，Lynch HT ，Neuhausen S ，Metcalfe KA ，Thompson I ，Murphy J ，Sun P ，Narod SA ... -  《-》

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Finch A ，Beiner M ，Lubinski J ，Lynch HT ，Moller P ，Rosen B ，Murphy J ，Ghadirian P ，Friedman E ，Foulkes WD ，Kim-Sing C ，Wagner T ，Tung N ，Couch F ，Stoppa-Lyonnet D ，Ainsworth P ，Daly M ，Pasini B ，Gershoni-Baruch R ，Eng C ，Olopade OI ，McLennan J ，Karlan B ，Weitzel J ，Sun P ，Narod SA ，Hereditary Ovarian Cancer Clinical Study Group ... -  《-》

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K ，Lynch HT ，Foulkes WD ，Tung N ，Kim-Sing C ，Olopade OI ，Eisen A ，Rosen B ，Snyder C ，Gershman S ，Sun P ，Narod SA ... -  《-》

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Olivier RI ，van Beurden M ，Lubsen MA ，Rookus MA ，Mooij TM ，van de Vijver MJ ，van't Veer LJ ... -  《-》

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations.

Kotsopoulos J ，Gronwald J ，Huzarski T ，Møller P ，Pal T ，McCuaig JM ，Singer CF ，Karlan BY ，Aeilts A ，Eng C ，Eisen A ，Bordeleau L ，Foulkes WD ，Tung N ，Couch FJ ，Fruscio R ，Neuhausen SL ，Zakalik D ，Cybulski C ，Metcalfe K ，Olopade OI ，Sun P ，Lubinski J ，Narod SA ，Hereditary Breast Cancer Clinical Study Group ... -  《-》